Lupin gets USFDA nod to market generic medication

Lupin has gained approval from the USFDA to market generic Valbenazine Capsules, used to treat tardive dyskinesia. This medication is equivalent to Neurocrine Biosciences, Inc's Ingrezza Capsules. Lupin is among the first applicants for this generic drug, entitling them to 180 days of shared exclusivity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/inV9PcK
via IFTTT